Other names: ZNF145 (zinc finger protein 145) Location: 11q23.1 Local order: centromeric to MLL. 
DNA/RNA

Expression
Highly specific for hematopoietic cells; during mouse development, PLZF is expressed in embryonic tissus, giving rise to hematopoietic progenitors; in man, PLZF is expressed in CD34+ progenitor cells and in primitive multipotent hematopoietic cell lines; PLZF levels decrease progressively with cell maturation and also with maturation induced by ATRA treatment.
Localisation
Nuclear; immunodetection shows a nuclear speckeled distribution of PLZF, resulting from a localization on discrete nuclear bodies whose formation is dependent on the integrity of the BTB/POZ domain.
Function
Putative transcription factor associated with myeloid differentiation; sequence specific DNA binding activity; in co-transfection experiments, PLZF has been shown to represse the transcription.
Homology
With the zinc finger MZF-1.
Implicated in t(11;17)(q23;q21) in M3 ANLL →
PLZF/RARA
Disease Acute promyelocytic leukaemia with a 'variant' translocation. Prognosis Worse prognosis than M3 ANLL with t(15;17), because the patients fail to respond to the maturation effect of ATRA. Cytogenetics t(11;17), like t(15;17)(q22;q21), and like another t(11;17)(q13;q21), with a discrete breakpoint in 11q13 are closely related to t(15;17)(q22;q21).
ZBTB16 (zinc finger and BTB domain containing 16)
Viguié F Atlas Genet Cytogenet Oncol Haematol. 1998; 2(3) Hybrid/Mutated Gene Both fusion transcripts are expressed.
Abnormal Protein
The two fusion proteins are produced; the PLZF/RARa protein contains the N-terminal BTB/POZ domain and two out of the nine zinc finger domains from PLZF; the POZ domain is largely responsible for the activity of PLZF/RARa fusion protein.
